Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Coherus | Rare Historical Photos

Coherus Oncology Q1 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year. On the company’s first-quarter 2026 earnings call

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Coherus's Refiling For Head and Neck Cancer Candidate Accepted By FDA For Review

Coherus's Refiling For Head and Neck Cancer Candidate Accepted By FDA For Review

Coherus BioSciences (NASDAQ: CHRS) announced that the United States Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for Toripalimab in combination with Gemcitabine and Cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasophar

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter

Coherus and Junshi Biosciences Receive CRL from FDA for Toripalimab in combination with Gemcitabine and Cisplatin In metastatic nasopharyngeal carcinoma (NPC)

Shanghai Junshi Biosciences and Coherus BioSciences, Inc. (NASDAQ: CHRS) received a complete response letter (CRL) from the U.S.

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ:CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck which originates in the nasopharynx, located behind the nose and above the back of the throat. The…

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.

inkl

Read news from The Economist, FT, and more,
with one subscription

Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting

Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ:CHRS) have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC). As of October 31, 2021, at the final analysis, a significant improvement in PFS was detected in the…

Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices

Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices

Coherus BioSciences Inc's (NASDAQ: CHRS)

1

Organisations

Food and Drug Administration

BristolMyers Squibb Company

BristolMyers Squibb

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

418,650 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play